A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers

Overview of attention for article published in Frontiers in Pharmacology, August 2019

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 1,074 followers.

A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers https://t.co/7LisbJj5tt

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.